Literature DB >> 3490942

Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro.

D K Henderson, V L Kan, J E Bennett.   

Abstract

Ten patients cured of cryptococcosis and 14 normal volunteers were immunized with subcutaneous injections of cryptococcal polysaccharide (CPS). Peripheral mononuclear cells cultured from the volunteers 7 days post-immunization secreted significant amounts of IgM, IgA and IgG antibody to CPS in vitro. In cell cultures obtained 7 days after immunization of patients, nine of 10 had neither IgM nor IgG antibody response to CPS, and eight lacked anti-CPS IgA. Depletion of T lymphocytes from patients' cell cultures did not promote specific antibody secretion to CPS by B cells. The intense, prolonged antigenaemia with CPS that accompanies cryptococcosis may be responsible for the failure of cured patients to have circulating anti-CPS-secreting cells after immunization.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490942      PMCID: PMC1542489     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  Studies on pneumococcal polysaccharide. II. Mechanism involved in production of immunological paralysis by type I pneumococcal polysaccharide.

Authors:  O K STARK
Journal:  J Immunol       Date:  1955-02       Impact factor: 5.422

2.  Isolation of B and T lymphocytes by nylon fiber columns.

Authors:  C Werner; P T Klouda; M C Corréa; P Vassalli; M Jeannet
Journal:  Tissue Antigens       Date:  1977-04

3.  Natural T-cell regulation of spontaneous immunoglobulin secretion.

Authors:  S L Andrew; A J Strelkauskas; S E Kurtz; K O'Connell; C L Reinisch
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

4.  Studies on immunological paralysis. 3. Recirculation and antibody-neutralizing activity of 14C-labelled type 3 pneumococcal polysaccharide in paralysed mice.

Authors:  J G Howard; G H Christie; M J Jacob; J Elson
Journal:  Clin Exp Immunol       Date:  1970-10       Impact factor: 4.330

5.  Prognostic factors in cryptococcal meningitis. A study in 111 cases.

Authors:  R D Diamond; J E Bennett
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

6.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

7.  T cell enrichment and depletion of human peripheral blood mononuclear cell preparations. Unexpected findings in the study of the functional activities of the separated populations.

Authors:  R M Falkoff; M Peters; A S Fauci
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

8.  Depletion of monocytes from human peripheral blood mononuclear leukocytes: comparison of the sephadex G-10 column method with other commonly used techniques.

Authors:  T R Jerrells; J H Dean; G L Richardson; R B Herberman
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis.

Authors:  D K Henderson; J E Bennett; M A Huber
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

10.  Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation.

Authors:  D J Volkman; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

View more
  8 in total

1.  Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.

Authors:  D L Goldman; S C Lee; A J Mednick; L Montella; A Casadevall
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 4.  Current concepts in cryptococcosis.

Authors:  T F Patterson; V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

Review 5.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.

Authors:  M F Miller; T G Mitchell
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

Review 8.  What makes Cryptococcus neoformans a pathogen?

Authors:  K L Buchanan; J W Murphy
Journal:  Emerg Infect Dis       Date:  1998 Jan-Mar       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.